COVID-19 Genomic RNA

The Scientists, Professors, Research scholars, Doctors can publish their high quality papers for worldwide viability on our online platform. This Genetics journal is using Editorial Tracking System for online manuscript submission. Manuscript can be submitted through online portal system https://www.longdom.org/submissions/genetic-syndromes-gene-therapy.html

Journal of Genetic Syndromes & Gene Therapy has NLM ID: 101574143: Index Copernicus Value 2016: 84.15

New coronavirus carries its mysterious genome in the form of a very long ribonucleic acid (RNA) molecule. Grappling with COVID-19 pandemic, the world seems to be lost with no sense of direction in uncovering what this coronavirus (SARS-Cov-2) is composed of. Being an RNA virus, SARS-Cov-2 enters host cells and replicates a genomic RNA and produces many smaller RNAs. These sub genomic RNAs are used for the synthesis of various proteins (spikes, envelopes, etc.) that are required for the beginning of SARS-Cov-2 lineage. Thus, the smaller RNAs make good targets for messing up new coronavirus's conquering of our immune system. Though recent studies reported the sequence of the RNA genome, they only predicted where their genes might be, leaving the world still drown in disorientation.

Best Regards

Christiane Zweier

Journal co-ordinator

Journal of Genetic Syndromes & Gene Therapy